U.S. Digital Therapeutics Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity, CNS Diseases, Others), By End Use (Patients, Providers, Payers, Employers, Others)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. Digital Therapeutics market size was exhibited at USD 4.71 billion in 2022 and is projected to hit around USD 26.11 billion by 2032, growing at a CAGR of 26.11% during the forecast period 2023 to 2032.

U.S. Digital Therapeutics market size

Key Pointers:

  • The patient end-user segment dominated the overall market with more than 33.9% of the revenue share in 2022. 
  • Diabetes dominated the application segment in 2022 with more than 28.9% of the revenue share.
  • Digital therapeutics solutions find application in 3 key product categories — products to manage a condition, treat a disease, and improve a health function; as such, the demand for these solutions is expected to increase in the coming years owing to the rising burden of chronic disorders
  • Based on end-use, the patient segment held the largest revenue share in 2022, owing to the increased adoption of healthcare IT services through AI-driven smartphone apps
  • In the wake of the COVID-19 pandemic, patients with chronic diseases have been facing challenges in managing medications, visiting healthcare providers, and maintaining a balanced diet. DTx therapy can be useful in managing patient conditions remotely
  • In January 2022, Pear Therapeutics and Crossroads Treatment Centers entered into a partnership to incorporate reSET-O PDT in several opioid use disorder treatment centers located in Pennsylvania, thereby enhancing its market reach

U.S. Digital Therapeutics Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 5.59 Billion

Market Size by 2032

USD 26.11 Billion

Growth Rate from 2023 to 2032

CAGR of 26.11%

Base year

2022

Forecast period

2023 to 2032

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Application, End use

Key companies profiled

Omada Health Inc.; Teladoc Health, Inc.; 2Morrow Inc.; Propeller Health (ResMed); Fitbit Health Solutions; Canary Health; WellDoc, Inc.; Noom, Inc.; Pear Therapeutics, Inc.; Click Therapeutics, Inc.; Akili Interactive Labs, Inc.; Better Therapeutics, Inc

 

Growing healthcare consumerism, the availability & development of DTx products, and the rising number of market players are driving the regional market.

SparkRx by Limbix Health, for example, is a digital therapeutic that is indicated for the treatment of adolescent depression. It is available without a prescription since the COVID-19 pandemic, under the FDA’s emergency guidance for digital health devices used in the treatment of psychiatric disorders. The COVID-19 pandemic has expedited the adoption of DTx, especially concerning mental illness and chronic ailments like diabetes and CVS. The U.S. FDA released new guidelines for computerized behavioral therapy and other DTx solutions during this public health emergency.

The organization has waived off guidelines that include 510(k) premarket notifications, registration & listing requirements, and Unique Device Identification (UDI) requirements for DTx therapeutic devices with low risk. For instance, Pear therapeutics launched Pear-004 for psychosis and self-management training post the introduction of the new guidelines. The product needs to be used under a doctor’s supervision.

The need for cost-effective healthcare is increasing globally due to rising healthcare expenditure. Digital health technology is being encouraged and preferred to avoid unnecessary costs and promote cheaper, alternative means of healthcare delivery, thus propelling the market. Moreover, the rising demand for remote monitoring services due to the increasing incidences of chronic diseases worldwide is one of the factors propelling the market growth. Digital therapeutic applications allow patients to manage and treat diseases without constant medical intervention, thereby drastically reducing the healthcare expenditure.

Application Insights

Diabetes dominated the application segment in 2022 with more than 28.9% of the revenue share. Diabetes prevalence is growing rapidly and is linked to blindness, heart attack, kidney failure, stroke, and gangrene in severe cases. Digital therapeutics are being used for the management & prevention of diseases by helping patients change their behavior through constant monitoring, thus improving their health in the long run.

Based on application, the U.S. digital therapeutics market is segmented into diabetes, obesity, CVD, respiratory diseases, smoking cessation, CNS diseases, and others. The CNS diseases segment is expected to show significant growth during the forecast period, owing to the increasing incidence of neurological diseases in the U.S. Alzheimer’s disease, expressive aphasia, degenerative diseases, Huntington’s disease, multiple sclerosis, and Parkinson’s disease are some of the most common neurological diseases that affect a growing proportion of the U.S. population.

Several digital therapeutics companies have been catering to the specific needs of Central Nervous System (CNS) disease patients to reduce anxiety and keep track of their daily activities. The demand has increased after the nationwide lockdown brought on by the COVID-19 pandemic.

According to a KFF tracking poll, around 47% of Americans staying at home have reported negative mental health effects as of March 2020. Out of them, over 21% have reported a major negative impact on their mental health. The FDA has released new guidelines for the computerized behavioral therapy and other DTx solutions during this public health emergency, which is expected to fuel the growth.

End-use Insights

The patient end-user segment dominated the overall market with more than 33.9% of the revenue share in 2022. The increased adoption of these tools can be attributed to their added benefits, one of which is effective health management at an affordable cost. In addition, the presence of advanced healthcare IT solutions and supportive government programs in the country are factors expected to further boost the adoption of digital therapeutics by patients.

Based on end-use, the market is segmented into patients, providers, payers, employers, & other end-users. The employer segment is expected to show notable growth during the forecast period. Employers are focusing on the management of employee healthcare costs, which is expected to drive segment growth. Moreover, growing awareness through employee healthcare programs is expected to propel the adoption of digital therapeutics for maintaining employee wellbeing.

The availability of various mHealth apps, such as Vida Health, used by payers, providers, and employers to monitor chronic conditions such as prediabetes, obesity, hypertension, & mental health issues, is another factor expected to propel market growth.

Some of the prominent players in the U.S. Digital Therapeutics Market include:

  • Omada Health Inc.
  • Teladoc Health, Inc.
  • 2Morrow Inc.
  • Propeller Health (ResMed)
  • Fitbit Health Solutions
  • Canary Health
  • WellDoc, Inc.
  • Noom, Inc.
  • Pear Therapeutics, Inc.
  • Click Therapeutics, Inc.
  • Akili Interactive Labs, Inc.
  • Better Therapeutics, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Digital Therapeutics market.

By Application 

  • Diabetes
  • Obesity
  • CVD
  • Respiratory Diseases
  • Smoking Cessation
  • CNS Disease
  • Others

By End-use 

  • Patients
  • Providers
  • Payers
  • Employers
  • Others

Chapter 1. Methodology And Scope
                   1.1 Market Segmentation And Scope
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 Nova one advisor’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details Of Primary Research
                   1.4 Information Or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                   1.7 List Of Secondary Sources
Chapter 2. Executive Summary
                   2.1 U.S. Digital Therapeutics Market Summary
Chapter 3. U.S. Digital Therapeutics Market Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent Market Outlook
                       3.1.2 Related/Ancillary Market Outlook
                   3.2. Penetration & Growth Prospect Mapping, 2023
                   3.3 U.S. Digital Therapeutics Market Dynamics
                       3.3.1 Market Driver Analysis
                       3.3.2 Market Restraint Analysis
                       3.3.3. Market Opportunity Analysis
                       3.3.4. Market Challenge Analysis
                   3.4 U.S. Digital Therapeutics Market Analysis Tools: Porter’s Five Forces
                       3.4.1 Supplier Power
                       3.4.2 Buyer Power
                       3.4.3 Substitution Threat
                       3.4.4 Threat Of New Entrants
                       3.4.5 Competitive Rivalry
                   3.5 U.S. Digital Therapeutics Industry Analysis - Pest (Political & Legal, Economic, Social, And Technological)
                       3.5.1 Political/Legal Landscape
                       3.5.2 Economic Landscape
                       3.5.3 Social Landscape
                       3.5.4 Technology Landscape
                   3.6. Regulatory & Reimbursement Scenario
Chapter 4. Covid-19 Impact Analysis
                   4.1 Covid-19 Prevalence Analysis
                   4.2. Current Impact & Future Scenario
                   4.3. Impact On Market Players
Chapter 5. U.S. Digital Therapeutics Market: Segment Analysis, By Application, 2020 - 2032
                   5.1 Application Market Share Analysis, 2023 & 2032
                   5.2 U.S. Digital Therapeutics Market, By Application, 2020 To 2032
                   5.3 Diabetes
                       5.3.1 Diabetes Market, 2020 - 2032
                   5.4 Obesity
                       5.4.1 Obesity Market, 2020 - 2032
                   5.5 CVD
                       5.5.1 CVD Market, 2020 - 2032
                   5.6 Respiratory Diseases
                       5.6.1 Respiratory Diseases Market, 2020 - 2032
                   5.7 Smoking Cessation
                       5.7.1 Smoking Cessation Market, 2020 - 2032
                   5.8 CNS Disease
                       5.8.1 CNS Disease Market, 2020 - 2032
                   5.9 Others
                       5.9.1 Others Market, 2020 - 2032
Chapter 6. U.S. Digital Therapeutics Market: Segment Analysis, By End Use, 2020 - 2032
                   6.1 End-Use Market Share Analysis, 2023 & 2032
                   6.2 U.S. Digital Therapeutics Market, By End Use, 2020 To 2032
                   6.3 Patients
                       6.3.1 Patients Market, 2020 - 2032
                   6.4 Providers
                       6.4.1 Providers Market, 2020 - 2032
                   6.5 Payers
                       6.5.1 Payers Market, 2020 - 2032
                   6.6 Employers
                       6.6.1 Employers Market, 2020 - 2032
                   6.6 Others
                       6.6.1 Others Market, 2020 - 2032
Chapter 7. U.S. Digital Therapeutics Market - Competitive Analysis
                   7.1 Market Participant Categorization
                       7.1.1. Company Market Position Analysis
                       7.1.2. Synergy Analysis: Major Deals & Strategic Alliances
                       7.1.3. Market Leaders & Innovators
                   7.2. List Of Key Companies
Chapter 8. U.S. Digital Therapeutics Market - Company Profiles
                   8.1 Omada Health Inc.
                       8.1.1 Company Overview
                       8.1.2 Financial Performance
                       8.1.3 End-Use Benchmarking
                       8.1.4 Strategic Initiatives
                   8.2 Teladoc Health, Inc.
                       8.2.1 Company Overview
                       8.2.2 Financial Performance
                       8.2.3 End-Use Benchmarking
                       8.2.4 Strategic Initiatives
                   8.3 2morrow Inc.
                       8.3.1 Company Overview
                       8.3.2 Financial Performance
                       8.3.3 End-Use Benchmarking
                       8.3.4 Strategic Initiatives
                   8.4 Propeller Health (Resmed)
                       8.4.1 Company Overview
                       8.4.2 Financial Performance
                       8.4.3 End-Use Benchmarking
                       8.4.4 Strategic Initiatives
                   8.5 Fitbit Health Solutions
                       8.5.1 Company Overview
                       8.5.2 Financial Performance
                       8.5.3 End-Use Benchmarking
                       8.5.4 Strategic Initiatives
                   8.6 Canary Health
                       8.6.1 Company Overview
                       8.6.2 Financial Performance
                       8.6.3 End-Use Benchmarking
                       8.6.4 Strategic Initiatives
                   8.7 Welldoc, Inc.
                       8.7.1 Company Overview
                       8.7.2 Financial Performance
                       8.7.3 End-Use Benchmarking
                       8.7.4 Strategic Initiatives
                   8.8 Noom, Inc.
                       8.8.1 Company Overview
                       8.8.2 Financial Performance
                       8.8.3 End-Use Benchmarking
                       8.8.4 Strategic Initiatives
                   8.9 Pear Therapeutics, Inc.
                       8.9.1 Company Overview
                       8.9.2 Financial Performance
                       8.9.3 End-Use Benchmarking
                       8.9.4 Strategic Initiatives
                   8.10 Click Therapeutics, Inc.
                       8.10.1 Company Overview
                       8.10.2 Financial Performance
                       8.10.3 End-Use Benchmarking
                       8.10.4 Strategic Initiatives
                   8.11 Akili Interactive Labs, Inc.
                       8.11.1 Company Overview
                       8.11.2 Financial Performance
                       8.11.3 End-Use Benchmarking
                       8.11.4 Strategic Initiatives
                   8.12 Better Therapeutics, Inc
                       8.12.1 Company Overview
                       8.12.2 Financial Performance
                       8.12.3 End-Use Benchmarking
                       8.12.4 Strategic Initiatives

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers